30 closest matches · ranked by relevance
Sarcoma
Primary: Patients With Response (Confirmed Complete, and Partial) With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor When Treated With Erlotinib. — 0…
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Plexiform Neurofibroma
Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants
Malignant Peripheral Nerve Sheath Tumors · MPNST · Sarcoma
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at ≥ 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination…
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Neurofibromatosis 2 · Vestibular Schwannoma
Primary: Estimated Volumetric Progression Free Survival at 12 Months — 70.6 Liklihood of PFS at 12 months
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Neurofibromatosis Type 1 · Sarcoma
Primary: Number of Participants With Response Rate (Complete Response and Partial Response) — 5; 4; 0; 0 Participants
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Neurofibromatosis
Primary: Percent Change From Baseline in Tumor Volume at 6 Months — 17 percentage change of tumor volume
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Neuroendocrine Tumors
Primary: Best Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Upon Central Radiologic Assessment — 0; 0; 23; 9 Participants
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants
Neurofibromatosis · NF1 · Neurofibromas
Primary: Disease Response — 0; 0; 2; 1 Participants